Sildenafil is a substrate for CYP 3A4 and 2C9 and is a weak inhibitor of CYP 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4. Clinical studies have shown no significant potential for CYP 3A4 or 2C9 induction or inhibition.

Sildenafil is a phosphodiesterase type-5 inhibitor.

Sildenafil is a vasoactive agent used to treat erectile dysfunction, and can also be used to reduce symptoms in patients with pulmonary arterial hypertension (PAH). It is administered orally or intravenously.

Sildenafil is metabolized by N-demethylation, mainly by CYP3A4 but also to some extent by CYP2C9. Elimination half-life is 3-5 hours. In vitro studies has show that Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4. Interaction studies have shown no significant alteration in the activities of CYP 3A4 or 2C9.